Intellia Therapeutics Inc (FRA:38I)
€ 13.565 -0.175 (-1.27%) Market Cap: 1.44 Bil Enterprise Value: 903.64 Mil PE Ratio: 0 PB Ratio: 1.53 GF Score: 57/100

Q2 2022 Intellia Therapeutics Inc Earnings Call Transcript

Aug 04, 2022 / 12:00PM GMT
Release Date Price: €69.54 (-1.56%)
Operator

Good morning, and welcome to the Intellia Therapeutics Second Quarter 2022 Financial Results Conference Call. My name is Andrew and I will be your conference operator today. Following formal remarks, we will open the call up for a question-and-answer session. This conference is being recorded at the company's request and will be available on the company's website following the end of the call. (Operator Instructions)

I will now turn the conference over to Ian Karp, Senior Vice President of Investor Relations and Corporate Communications at Intellia. Please proceed.

Ian Karp
Intellia Therapeutics, Inc. - SVP of IR & Corporate Communications

Thank you, operator, and good morning, everyone. Welcome to Intellia Therapeutics Second Quarter 2022 Earnings Call. Earlier this morning, Intellia issued a press release outlining the company's progress this quarter, as well as topics for discussion on today's call. This release can be found on the Investors & Media section of Intellia's website at intelliatx.com. This call is being broadcast live and a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot